Report
Thomas Vranken

Merus Raises $ 300m through public offering

Merus has announced a public offering of 5.26m shares at $57 per share, an 8.6% discount to the previous close, to raise approx. $300 million in gross proceeds. The proceeds from the offering will fund clinical and preclinical development, technology advancement, and general corporate needs. Following strong ASCO 2025 data and a resulting share price increase, the transaction strengthens Merus' financial position beyond its solid 1Q25 cash position of $638m. We have raised the probability of success for petosemtamab in 1L HNSCC, prompting a TP increase from $59 to $66 while reiterating a Buy rating.
Underlying
MERUS B V

Provider
KBC Securities
KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

 

Analysts
Thomas Vranken

Other Reports on these Companies
Other Reports from KBC Securities
Hilde Van Boxstael ... (+4)
  • Hilde Van Boxstael
  • Lynn Hautekeete
  • Thibault Leneeuw
  • Thomas Couvreur

ResearchPool Subscriptions

Get the most out of your insights

Get in touch